Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

1.0% IP-001 for injection

Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation

PROCEDURE

Surgical Resection and Local Ablation

Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)

PROCEDURE

Local Ablation Alone

Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone

Trial Locations (1)

40202

RECRUITING

University of Louisville, Louisville

All Listed Sponsors
lead

Robert C. Martin

OTHER